MiR-101 functions as a tumor suppressor by directly targeting nemo-like kinase in liver cancer

Cancer Letters

Volumn 344, Issue 2, 2014, Pages 204-211

  Shen, Qingyu ^a   Bae, Hyun Jin ^a   Eun, Jung Woo ^a   Kim, Hyung Seok ^a   Park, Se Jin ^a   Shin, Woo Chan ^a   Lee, Eun Kyung ^a   Park, Soha ^b   Park, Won Sang ^a   Lee, Jung Young ^a   Nam, Suk Woo ^a  

^a The Catholic University of Korea   (South Korea)

^b Yonsei University   (South Korea)

Author keywords

Liver cancer; MiR 101; NLK; Tumor suppressor

Indexed keywords

MICRORNA 101; MITOGEN ACTIVATED PROTEIN KINASE; NEMO LIKE KINASE; UNCLASSIFIED DRUG;

ARTICLE; CANCER INHIBITION; CANCER TISSUE; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REGULATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE SILENCING; HEPATOMA CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CANCER; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN TARGETING; REAL TIME POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR GENE;

LIVER CANCER; MIR-101; NLK; TUMOR SUPPRESSOR;

CELL LINE, TUMOR; DOWN-REGULATION; GENE KNOCKDOWN TECHNIQUES; HUMANS; I-KAPPA B KINASE; LIVER NEOPLASMS; MICRORNAS; TRANSFECTION;

EID: 84893680182     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.10.030     Document Type: Article

References (32)

1. Hb E.S. Hepatocellular carcinoma. N. Engl. J. Med. 2011, 365:1118-1127.
2. Bruix B.L., Sala M., Llovet J.M. Focus on hepatocellular carcinoma. Cancer Cell 2004, 5:215-219.
3. Brott BK P.B., Erikson R.L. Nlk is a murine protein kinase related to Erk/MAP kinases and localized in the nucleus. Proc. Natl. Acad. Sci. USA 1998, 95:963-968.
4. Ishitani T., Ishitani S. Nemo-like kinase, a multifaceted cell signaling regulator. Cell Signal 2013, 25:190-197.
5. Ota S., Ishitani S., Shimizu N., Matsumoto K., Itoh M., Ishitani T. NLK positively regulates Wnt/beta-catenin signalling by phosphorylating LEF1 in neural progenitor cells. EMBO J. 2012, 31:1904-1915.
6. Ishitani T., Hirao T., Suzuki M., Isoda M., Ishitani S., Harigaya K., Kitagawa M., Matsumoto K., Itoh M. Nemo-like kinase suppresses Notch signalling by interfering with formation of the Notch active transcriptional complex. Nat. Cell Biol. 2010, 12:278-285.
7. Kanei-Ishii C., Ninomiya-Tsuji J., Tanikawa J., Nomura T., Ishitani T., Kishida S., Kokura K., Kurahashi T., Ichikawa-Iwata E., Kim Y., Matsumoto K., Ishii S. Wnt-1 signal induces phosphorylation and degradation of c-Myb protein via TAK1, HIPK2, and NLK. Genes. Dev. 2004, 18:816-829.
8. Jung K.H., Kim J.K., Noh J.H., Eun J.W., Bae H.J., Xie H.J., Ahn Y.M., Park W.S., Lee J.Y., Nam S.W. Targeted disruption of Nemo-like kinase inhibits tumor cell growth by simultaneous suppression of cyclin D1 and CDK2 in human hepatocellular carcinoma. J. Cell. Biochem. 2010, 110:687-696.
9. Emami K.H., Brown L.G., Pitts T.E., Sun X., Vessella R.L., Corey E. Nemo-like kinase induces apoptosis and inhibits androgen receptor signaling in prostate cancer cells. Prostate 2009, 69:1481-1492.
10. Cui G., Li Z., Shao B., Zhao L., Zhou Y., Lu T., Wang J., Shi X., Wang J., Zuo G., Zhu W., Shen A. Clinical and biological significance of nemo-like kinase expression in glioma. J. Clin. Neurosci. 2011, 18:271-275.
11. Dp B. MicroRNAs Genomics, Biogenesis, Mechanism, and Function, Cell 2004, 116:281-297.
12. M. Garofalo, C.M. Croce, microRNAs: master regulators as potential therapeutics in cancer, Annu. Rev. Pharmacol. Toxicol. 51 25-43.
13. Calin G.A., Croce C.M. MicroRNA signatures in human cancers. Nat. Rev. Cancer 2006, 6:857-866.
14. Xiong Y., Fang J.H., Yun J.P., Yang J., Zhang Y., Jia W.H., Zhuang S.M. Effects of microRNA-29 on apoptosis, tumorigenicity, and prognosis of hepatocellular carcinoma. Hepatology 2010, 51:836-845.
15. Li W., Xie L., He X., Li J., Tu K., Wei L., Wu J., Guo Y., Ma X., Zhang P., Pan Z., Hu X., Zhao Y., Xie H., Jiang G., Chen T., Wang J., Zheng S., Cheng J., Wan D., Yang S., Li Y., Gu J. Diagnostic and prognostic implications of microRNAs in human hepatocellular carcinoma. Int. J. Cancer 2008, 123:1616-1622.
16. Kim J.K., Noh J.H., Jung K.H., Eun J.W., Bae H.J., Kim M.G., Chang Y.G., Shen Q., Park W.S., Lee J.Y., Borlak J., Nam S.W. Sirtuin7 oncogenic potential in human hepatocellular carcinoma and its regulation by the tumor suppressors MiR-125a-5p and MiR-125b. Hepatology 2013, 57:1055-1067.
17. J.H. Noh, Y.G. Chang, M.G. Kim, K.H. Jung, J.K. Kim, H.J. Bae, J.W. Eun, Q. Shen, S.J. Kim, S.H. Kwon, W.S. Park, J.Y. Lee, S.W. Nam, MiR-145 functions as a tumor suppressor by directly targeting histone deacetylase 2 in liver cancer, Cancer Lett. 335 455-462.
18. Wang L., Zhang X., Jia L.T., Hu S.J., Zhao J., Yang J.D., Wen W.H., Wang Z., Wang T., Zhao J., Wang R.A., Meng Y.L., Nie Y.Z., Dou K.F., Chen S.Y., Yao L.B., Fan D.M., Zhang R., Yang A.G. c-Myc-mediated epigenetic silencing of microRNA-101 contributes to dysregulation of multiple pathways in hepatocellular carcinoma. Hepatology 2013.
19. Choi K.W., Benzer S. Rotation of photoreceptor clusters in the developing Drosophila eye requires the nemo gene. Cell 1994, 78:125-136.
20. Calnan D.R., Brunet A. The FoxO code. Oncogene 2008, 27:2276-2288.
21. Tan Z., Li M., Wu W., Zhang L., Ding Q., Wu X., Mu J., Liu Y. NLK is a key regulator of proliferation and migration in gallbladder carcinoma cells. Mol. Cell Biochem. 2012, 369:27-33.
22. Yasuda J., Tsuchiya A., Yamada T., Sakamoto M., Sekiya T., Hirohashi S. Nemo-like kinase induces apoptosis in DLD-1 human colon cancer cells. Biochem. Biophys. Res. Commun. 2003, 308:227-233.
23. Lv L., Wan C., Chen B., Li M., Liu Y., Ni T., Yang Y., Liu Y., Cong X., Xue Q., Mao G. Nemo-like kinase (NLK) inhibits the progression of NSCLC via negatively modulating Wnt signaling pathway. J. Cell Biochem. 2013.
24. Li M., Zhang S., Wang Z., Zhang B., Wu X., Weng H., Ding Q., Tan Z., Zhang N., Mu J., Yang J., Shu Y., Bao R., Ding Q., Wu W., Cao Y., Liu Y. Prognostic significance of nemo-like kinase (NLK) expression in patients with gallbladder cancer. Tumour. Biol. 2013.
25. Garzon R., Marcucci G., Croce C.M. Targeting microRNAs in cancer: rationale, strategies and challenges. Nat. Rev. Drug Discov. 2010, 9:775-789.
26. Iorio M.V., Ferracin M., Liu C.G., Veronese A., Spizzo R., Sabbioni S., Magri E., Pedriali M., Fabbri M., Campiglio M., Menard S., Palazzo J.P., Rosenberg A., Musiani P., Volinia S., Nenci I., Calin G.A., Querzoli P., Negrini M., Croce C.M. MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 2005, 65:7065-7070.
27. Iorio M.V., Visone R., Di Leva G., Donati V., Petrocca F., Casalini P., Taccioli C., Volinia S., Liu C.G., Alder H., Calin G.A., Menard S., Croce C.M. MicroRNA signatures in human ovarian cancer. Cancer Res. 2007, 67:8699-8707.
28. Jiang J., Gusev Y., Aderca I., Mettler T.A., Nagorney D.M., Brackett D.J., Roberts L.R., Schmittgen T.D. Association of MicroRNA expression in hepatocellular carcinomas with hepatitis infection, cirrhosis, and patient survival. Clin. Cancer Res. 2008, 14:419-427.
29. Lui W.O., Pourmand N., Patterson B.K., Fire A. Patterns of known and novel small RNAs in human cervical cancer. Cancer Res. 2007, 67:6031-6043.
30. Yanaihara N., Caplen N., Bowman E., Seike M., Kumamoto K., Yi M., Stephens R.M., Okamoto A., Yokota J., Tanaka T., Calin G.A., Liu C.G., Croce C.M., Harris C.C. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 2006, 9:189-198.
31. Hang Su J.-R.Y., Xu Teng, Husang Jun, Xu Li, Yuan Yunfei, Zhuang Shi-Mei MicroRNA-101, down-regulated in hepatocellular carcinoma, promotes apoptosis and suppresses tumorigenicity. Cancer Res. 2009, 69:1135-1142.
32. Zhang Y., Guo X., Xiong L., Kong X., Xu Y., Liu C., Zou L., Li Z., Zhao J., Lin N. MicroRNA-101 suppresses SOX9-dependent tumorigenicity and promotes favorable prognosis of human hepatocellular carcinoma. FEBS Lett. 2012, 586:4362-4370.